🇺🇸 GENMAB A/SGMAB
Get GENMAB A/S filings on Telegram the moment they are published.
Follow GENMAB A/S on TelegramOne tap starts your 30-day free trial. No card needed.
Subject: 6-K — Foreign issuer report
Overview: Phase 3 EPCORE DLBCL-2 trial results show epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% in newly diagnosed DLBCL patients.
Source: SEC EDGAR · Original filing
Get filings like this in Telegram the moment they are published — for the companies you follow.
Start 30-day trial About Finterest